Sequential changes of [3H]forskolin, [3H]cyclohexyladenosine and [3H]PN200-110 binding sites in the brain of 6-hydroxydopamine-lesioned rats

Acta Physiologica Scandinavica

Volumn 169, Issue 1, 2000, Pages 71-78

  Araki, Tsutomu ^a,c   Tanji, H ^b   Kato, H ^b   Imai, Y ^c   Mizugaki, M ^a   Itoyama, Y ^b  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

6 hydroxydopamine; Adenosine A1 receptor; Adenylyl cyclase; Calcium channel; Rat; Receptor autoradiography

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENYLATE CYCLASE; CALCIUM CHANNEL; CYCLOHEXYLADENOSINE; DOPAMINE; DOPAMINE RECEPTOR; FORSKOLIN; OXIDOPAMINE; ADENOSINE; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ISRADIPINE; N(6) CYCLOHEXYLADENOSINE; N(6)-CYCLOHEXYLADENOSINE; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ISOTOPE LABELING; MALE; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; TIME; ANIMAL; BRAIN LEVEL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; MEDIAL FOREBRAIN BUNDLE; METABOLISM; NERVE DEGENERATION; PHYSIOLOGY; RADIOASSAY; WISTAR RAT;

ADENOSINE; ANIMALS; AUTORADIOGRAPHY; BINDING SITES; BRAIN CHEMISTRY; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CORPUS STRIATUM; FORSKOLIN; ISRADIPINE; MALE; MEDIAL FOREBRAIN BUNDLE; NERVE DEGENERATION; OXIDOPAMINE; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TRITIUM;

EID: 0034186118     PISSN: 00016772     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-201X.2000.00690.x     Document Type: Article

References (41)

1. 1 receptor antagonist in primate cells and interacts with other receptors. Eur J Pharmacol 364, 33-41.
2. Araki, T., Kato, H., Kogure, K. & Kanai, Y. 1992. Long-term changes in gerbil brain neurotransmitter receptors following transient cerebral ischaemia. Br J Pharmacol 107, 437-442.
3. 1 and calcium antagonist binding sites in selectively vulnerable areas: an autoradiographic study of gerbil brain. J Neurol Sci 106, 206-212.
4. Araki, T., Tanji, H., Kato, H. & Itoyama, Y. 1998. Sequential changes of dopaminergic receptors in the rat after 6-hydroxydopamine lesions of the medial forebrain bundle. J Neurol Sci 160, 121-127.
5. Berger, K., Przedbroski, S. & Cadet, J.L. 1991. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injections in rats. Brain Res Bull 26, 301-307.
6. 3H]neurotensin binding by unilateral intrastriatal 6-hydroxydopamine injections: evidence from a receptor autoradiographic study. Brain Res 564, 37-44.
7. Dawson, T.M., Dawson, V.L., Gage, F.H., Fisher, L.J., Hunt, M.A. & Wamsley, J.K. 1991. Functional recovery of supersensitive dopamine receptors after intrastriatal grafts of fetal substantia nigra. Exp Neurol 111, 282-292.
8. 2+ channels. Neurosci Lett 145, 121-125.
9. 2 receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321, 143-147.
10. Fornstedt, B. 1990. Role of catechol autoxidation in the degeneration of dopamine neurons. Acta Neurol Scand 129, 12-14.
11. 1 receptors. Brain Res 710, 79-91.
12. Hökfelt, T. & Ungerstedt, U. 1973. Specificity of 6-hydroxydopamine induced degeneration of central monoamine neurones: an electron and fluorescence microscopic study with special reference to intracerebral injection on the nigro-striatal dopamine system. Brain Res 60, 269-297.
13. A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 24, 2857-2860.
14. König, J.F.R. & Klippel, R.A. 1963. The Rat brain: A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem. Williams and Wilkins, Baltimore.
15. Kruger, B.K., Forn, J., Walters, J.R., Roth, R.H. & Greengard, P. 1976. Stimulation by dopamine of adenosine cyclic-3′,5′-monophosphate formation in rat caudate nucleus: effects of lesions of the nigrostriatal pathway. Mol Pharmacol 12, 639-648.
16. Kupsch, A., Gerlach, M., Pupeter, S.C. et al. 1995. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport 6, 621-625.
17. Kupsch, A., Sautter, J., Riederer, P., Gerlach, M. & Oertel, W.H. 1996. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 741, 185-196.
18. 1 adenosine receptor from rat brain. Mol Pharmacol 40, 1-7.
19. Michel, P.P., Marien, M., Ruberg, M., Colpaert, F. & Agid, Y. 1999. Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes. J Neurochem 72, 2074-2082.
20. Morelli, M., Pinna, A., Wardas, J. & Di Chiara, G. 1995. Adenosine A2 receptors stimulates c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience 67, 49-55.
21. Murai, T., Koshikawa, N., Kanayama, T., Takada, K., Tomiyama, K. & Kobayashi, M. 1994. Opposite effects of midazolam and β-carboline-3-carboxylate ethyl ester on the release of dopamine from rat nucleus accumbens measured by in vivo microdialysis. Eur J Pharmacol 261, 65-71.
22. Nagatsu, T., Kanamori, T., Kato, T., Iizuka, R. & Narabayashi, H. 1978. Dopamine-stimulated adenylate cyclase activity in the human brain: changes in parkinsonism. Biochem Med 19, 360-365.
23. 2 receptor alterations on the contralateral side. Exp Neurol 121, 40-47.
24. Narang, N. & Wamsley, J.K. 1995. Time dependent changes in DA uptake sites, D1 and D2 receptor binding and mRNA after 6-OHDA lesions of the medial forebrain bundle in the rat brain. J Chem Neuroanal 9, 41-53.
25. Okada, Y. & Ozawa, S. 1980. Inhibitory action of adenosine on synaptic transmission in the hippocampus of the guinea pig in vitro. Eur J Pharmacol 68, 483-492.
26. 2 receptors mediating inhibition of adenylate cyclase in rats. Eur J Pharmacol 99, 127-128.
27. Palmer, T.M. & Stiles, G.L. 1995. Review: Neurotransmitter receptors VII: adenosine receptors. Neuropharmacology 34, 683-694.
28. Pifl, C., Nanoff, C., Schingnitz, G., Schütz, W. & Hornykiewicz, O. 1992. Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease. J Neurochem 58, 1997-2004.
29. Poat, J.A., Cripps, H.E. & Iversen, L.L. 1988. Differences between high-affinity forskolin binding sites in dopamine-rich and other regions of rat brain. Proc Natl Acad Sci USA 85, 3216-3220.
30. Pritzel, M., Sarter, M., Morgan, S. & Huston, J.P. 1983. Interhemispheric nigrostriatal projections in the rat: bifurcating nigral projections and loci of crossing in the diencephalon. Brain Res Bull 10, 385-390.
31. Pycock, C.J. 1980. Turning behavior in animals. Neuroscience 5, 461-514.
32. Rodnitzky, R. 1999. Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Drugs 57, 845-849.
33. Seamon, K. & Daly, J.W. 1981. Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem 256, 9799-9801.
34. Shibuya, M. 1979. Dopamine-sensitive adenylate cyclase activity in the striatum in the Parkinson's disease. J Neural Transm 44, 287-295.
35. 2 dopamine receptors in effluxes of cyclic AMP from neostriatum. Nature 294, 366-368.
36. Sunahara, R.K., Dessauer, D.W. & Gilman, A.G. 1996. Complexity and diversity of mammalian adenylate cyclases. Annu Rev Pharmacol Toxicol 36, 461-480.
37. Swanson, L.W. 1982. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 9, 321-353.
38. Thomas, K.L., Rose, S., Jenner, P. & Marsden, D. 1992. Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation. Biochem Pharmacol 44, 73-82.
39. Ungerstedt, U. & Arbuthnott, G. 1970. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 24, 485-493.
40. B-mediated synaptic current by adenosine recorded in vitro in midbrain dopamine neurons. J Pharmacol Exp Ther 273, 575-581.
41. Zigmond, M.J., Hastings, T.G. & Abercrombie, E.D. 1992. Neurochemical responses to 6-hydroxydopamine and L-DOPA therapy: implication for Parkinson's disease. Ann Neurol 32, 105-110.